Bryan F. Cox - Aug 10, 2023 Form 3 Insider Report for TriSalus Life Sciences, Inc. (TLSI)

Role: Chief Scientific & Manufact.
Signature: /s/ Sean Murphy, Attorney-in-Fact for Bryan Cox
Stock symbol: TLSI
Transactions as of: Aug 10, 2023
Transactions value $: $0
Form type: 3
Date filed: 8/14/2023, 07:05 PM
Next filing: Aug 14, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	TLSI	Common Stock						71.9K	Aug 10, 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	TLSI	Employee Stock Option (right to buy)							Aug 10, 2023	Common Stock	6.06K	$0.41	Direct	F1, F3
holding	TLSI	Employee Stock Option (right to buy)							Aug 10, 2023	Common Stock	8.39K	$10.30	Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The securities reported herein were acquired by the Reporting Person prior to the Reporting Person becoming an executive officer of the Issuer. The Reporting Person was appointed as an executive officer of the Issuer effective immediately after the effective time of the Merger (as defined in that certain Agreement and Plan of Merger, dated as of November 11, 2022, as amended, by and among the Issuer, MTAC Merger Sub, Inc., and TriSalus Operating Life Sciences, Inc.).
F2	Includes 4,127 shares issued pursuant to a restricted stock unit award ("RSU"). The RSU vests in four equal annual installments commencing on October 5, 2023, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.
F3	The option, originally for a total of 981,164 shares, vests in accordance with the following schedule: twenty-five percent of the shares subject to the option vested on June 29, 2021, the first anniversary of the vesting commencement date (the "VCD"), and the remainder vests in 36 equal monthly installments thereafter for the following three years, subject to the Reporting Person's continued service with the Issuer on each respective vesting date. The Reporting Person exercised an aggregate of 735,873 shares underlying such option that vested from the VCD.
F4	Twenty-five percent of the shares subject to the option vests on May 19, 2024, the first anniversary of the VCD, and the remainder vests in 36 equal monthly installments thereafter for the following three years, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.